N/A N=74 Impact of a Family History of Hypertension and Physical Activity on Left Ventricular Mass
Genetic Predisposition · Genetic Hypertension
Primary: Left Ventricular Mass — 155.1680523; 129.5013331 gram
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=114 Irbesartan and Atenolol in Hypertensive Heart Disease
Hypertension
Primary: Changes in Left Ventricular Mass Index — -1; -9; -6; -14 g/m^2
Phase 3 N=90 Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy
Hypertension; Hypertrophy, Left Ventricular
Primary: Change From Baseline in Left Ventricular Mass Index (LVMI) Measured Via Magnetic Resonance Imaging (MRI) — -7.1; -9.1 g/m˄2
Phase 3 N=287 The CLEVER Study - Coreg And Left Ventricular Mass Regression
Hypertrophy, Left Ventricular
Primary: Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Magnetic Resonance Imaging (MRI) at Month 12…
N/A N=53 Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function
Hypertension
Primary: Resting Systolic BP — 135 mm Hg — p=<0.05
Phase 3 N=460 Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension
Hypertension · Left Ventricular Hypertrophy · Overweight
Primary: Change in Left Ventricular Mass Index (LVMI) From Baseline to End of Study (Week 36) — -5.51; -4.81; -5.61 g/m^2
N/A N=123 Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients
Hypertension · High Blood Pressure · Ventricular Hypertrophy
Primary: Clinically Significant Difference in Blood Pressure Lowering, Health Status and Quality of Life — -3.3; -4.9 mm Hg
N/A N=120 Training-induced Increased Left Ventricular Trabeculation
Athletes Heart · Left Ventricular Hypertrabeculation
Primary: Thickness of Compacted Myocardial Tissue (cm) — 0.53; 0.56; 0.8; 0.85 cm — p=0.44
Phase 4 N=229 The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction
Hypertension · Diastolic Dysfunction
Primary: Change in Lateral Mitral Annular Myocardial Relaxation Velocity — 1.544; 1.476 cm/s
Phase 4 N=315 Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)
Hypertension · Left Ventricular Hypertrophy
Primary: Percent Change of B Type Natriuretic Peptides (BNP) Level — -29.2 Percent Change
Phase 2 N=389 Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension
Hypertension
Primary: Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) — -11.53; -10.98; -12.45; -3.69 mmHg
Phase 3 N=72 Impact of Diabetes on Left Ventricular Remodeling
Diabetes
Primary: Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) — 73.03; 78.06; 78.52; 79.03 ml/m^2
N/A N=36 Exercise,Metabolic Syndrome and Weight Regain (Echocardiography Substudy)
Metabolic Syndrome · Obesity
Primary: Mean Resting E/E' — 7.01 ml/min/kg — p==0.14
Phase 4 N=74 ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling
Hypertension · Left Ventricle Hypertrophy
Primary: Change From Baseline in C-terminal Propeptide of Procollagen Type I (PICP) — -5.22; -4.25 ug/l
Phase 2 N=46 Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy
Cardiomyopathy, Hypertrophic
Primary: Change From Baseline in Peak VO2 as Measured by Cardiopulmonary Exercise Test (CPET) — 1.00; 0.39 mL/kg/min — p=0.5506
Phase 2 N=20 Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy
Primary: Percentage Change From Baseline in Extent of Left Ventricular Fibrosis at 1 Year as Assessed by Magnetic Resonance Imaging. — -23; 31 Percentage change in fibrotic…
Phase 2 N=58 Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
Congestive Heart Failure
Primary: Change in Natriuresis (Urinary Sodium Excretion) in Control Subjects at 60 Minutes After Volume Expansion Compared to Baseline in Response to Placebo Treatment — 87.19…
Phase 2 N=44 Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction
Heart Failure · Congestive Heart Failure
Primary: Wave Reflection Magnitude — 0.38; 0.44; 0.37 dimensionless ratio
N/A N=812 Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Primary: Percentage of Participants With Cardiac Fixation at the Radionuclide Bone Scintigraphy and/or Single Photon Emission Computed Tomography (SPECT): FAS1 — 32.0 Percentage…
N/A N=60 Strategies for Aggressive Central Afterload Reduction in Patients With Heart Failure
Heart Failure
Primary: Change in Peak Oxygen Uptake (VO2) During Maximal Effort Exercise Stress Test According to Ejection Fraction Subgroups — 1.5; -0.5; 2.0; -1.0 percentage of change in…
Phase 4 N=50 BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF
Heart Failure With Preserved Ejection Fraction · Hypertension
Primary: Difference in Home Systolic Blood Pressure — 130.7; 134.5 mm Hg — p=0.017
Phase 3 N=261 Obese Hypertension Study (0954-315)
Hypertension
Primary: Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8 — -12.1; -6.8 mm Hg
N/A N=14 REmodeling the Left Ventricle With Atrial Modulated Pacing
Heart Failure
Primary: Number of Participants Who Remained on Study — 9; 4 participants
Phase 2 N=1,328 Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
Hypertension
Primary: Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) — -9.97; -12.92; -13.63; -9.14 mmHg
Phase 2 N=341 A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension
Essential Hypertension
Primary: Number of Participants With Adverse Events, Serious Adverse Events, and Deaths (Analysis by Actual Treatment) — 147; 78; 53; 0 Participants
Phase 4 N=70 Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart
Hypertension · Left Ventricular Diastolic Dysfunction
Primary: Improvement in Exercise Tolerance — 9; 8 Participants
Phase 2 N=32 Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers
Hypertension
Primary: 24-hour Urinary Sodium Excretion — 220.58; 198.73; 177.40; 146.18 mmol/24 hours
Phase 2 N=21 A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Cardiomyopathy, Hypertrophic Obstructive · Left Ventricular Outflow Tract Obstruction
Primary: Change in Post-exercise Peak LVOT Gradient From Baseline to Week 12 — -89.5; -25.0 mm Hg
Phase 4 N=465 Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction
Heart Failure and Reduced Ejection Fraction
Primary: Change From Baseline in Aortic Characteristic Impedance at Week 12 — -0.7; -2.9 dyne x sec/cm5 — p=0.7827
N/A N=14 Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet in Diastolic Heart Failure
Diastolic Heart Failure · Hypertensive Heart Disease
Primary: Brachial Artery Flow-mediated Dilation (FMD) — 5; 8 % dilation — p=.17